Seres Therapeutics (NASDAQ:MCRB) Shares Gap Up to $8.06

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) gapped up prior to trading on Thursday . The stock had previously closed at $8.06, but opened at $8.36. Seres Therapeutics shares last traded at $8.24, with a volume of 1,679 shares trading hands.

Separately, Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $20.83.

The company has a quick ratio of 3.79, a current ratio of 3.79 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average is $8.84 and its 200-day moving average is $9.12. The company has a market cap of $738.45 million, a PE ratio of -21.16 and a beta of 3.44.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, November 10th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of ($0.47) by $1.19. Seres Therapeutics had a negative net margin of 21.79% and a negative return on equity of 22.73%. The business had revenue of $126.73 million for the quarter, compared to analyst estimates of $7.12 million. During the same quarter in the previous year, the firm posted ($0.36) earnings per share. As a group, equities research analysts anticipate that Seres Therapeutics, Inc. will post -0.63 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Seres Therapeutics by 25.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,458 shares of the biotechnology company’s stock worth $941,000 after buying an additional 7,979 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Seres Therapeutics by 17.7% in the second quarter. MetLife Investment Management LLC now owns 25,468 shares of the biotechnology company’s stock worth $607,000 after buying an additional 3,824 shares in the last quarter. Edgewood Management LLC lifted its stake in shares of Seres Therapeutics by 60.0% in the second quarter. Edgewood Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $954,000 after buying an additional 15,000 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Seres Therapeutics by 11.7% in the second quarter. Rhumbline Advisers now owns 78,847 shares of the biotechnology company’s stock worth $1,881,000 after buying an additional 8,244 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Seres Therapeutics in the third quarter worth approximately $186,000. Hedge funds and other institutional investors own 83.25% of the company’s stock.

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics, Inc engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Further Reading: What is a SEC Filing?

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.